Evidence map›Paper›PMID 39934300›Full record

ReviewEuropean journal of nuclear medicine and molecular imaging2025

The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.

Riccardo Laudicella, Matteo Bauckneht, Irene A Burger, Alberto Cacciola, Stefano Fanti, Andrea Farolfi, Vincenzo Ficarra, Andrei Iagaru, Virginia Liberini, Stefano Pergolizzi and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Is there a role for early SSTR-targeting PRRT in GEP-NET?European journal of nuclear medicine and molecular imaging · 2026
    Pooled it
  3. Article
  4. The predictive role of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Riccardo LaudicellaNuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy.ORCID 0000-0002-2842-0301
Matteo BaucknehtIRCCS Ospedale Policlinico San Martino, Genova, Italy.ORCID 0000-0002-1937-9116
Irene A BurgerDepartment of Nuclear Medicine, University Hospital Zürich, University of Zurich, Zurich, Switzerland. irene.burger@ksb.ch.ORCID 0000-0001-8029-8692
Alberto CacciolaBrain Mapping Lab, Department of Biomedical, Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.
Stefano FantiNuclear Medicine Division, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola, Bologna, Italy.
Andrea FarolfiNuclear Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy.ORCID 0000-0002-5443-4301
Vincenzo FicarraGaetano Barresi Department of Human and Paediatric Pathology, Urologic Section, University of Messina, Messina, Italy.
Andrei IagaruDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, USA.
Virginia LiberiniNuclear Medicine Unit, ASO S.Croce e Carle Cuneo, Cuneo, Italy.ORCID 0000-0001-9416-6965
Stefano PergolizziRadiation Oncology Unit, Department of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
Giulia SantoDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Irene VirgoliniDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Fabio MinutoliNuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy.
Sergio BaldariNuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeConventional systemic therapies are valuable options in prostate cancer (PCa); however, such treatments can determine adverse events and toxicity. The observed improvement in overall survival, coupled with PSA reduction and a favorable safety profile in the post-taxane castration-resistant PCa (CRPC) setting has prompted the consideration of PSMA-based radioligand therapy (RLT) earlier in the treatment sequence. In this review, we will describe the literature and ongoing clinical trials regarding the use of PSMA-based RLT in hormone-sensitive PCa (HSPC) including the neoadjuvant, de-novo/synchronous metastatic, adjuvant, and early BCR settings.

methodsWe performed a systematic literature search on the PubMed/MEDLINE/EMBASE and clinicaltrials.gov databases for studies and protocols assessing the role of PSMA-based RLT in HSPC.

resultsThe literature search yielded 140 results. After screening titles and abstracts and applying inclusion and exclusion criteria, we selected 25 papers showing the potentialities of earlier RLT in HSPC, with several ongoing trials.

conclusionEarly use of PSMA-based RLT holds significant potential in HSPC patients from the neoadjuvant to the BCR setting. In these stages, the lower tumor burden, more frequent exclusive nodal involvement, and higher organ reserve may improve treatment efficacy and allow for treatment combinations while maintaining a less toxic profile.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIProstatic NeoplasmsRadiopharmaceuticalsHumansLigandsMaleAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILigandsRadiopharmaceuticalsHSPCPCaProstate-specific membrane antigenRLTTheranostics

Identifiers

PMID39934300
PMCPMC12119734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.